Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASML Holding NV (ASML) vs Tenet Healthcare Corporation (THC) Price & Performance

ASML Holding NV
Tenet Healthcare Corporation

Price performance

Price movement over the last 24 hours

Key statistics

ASML Holding NV vs Tenet Healthcare Corporation — how do they compare? ASML Holding NV trades at $1,772.62 (market cap $688.66B), while Tenet Healthcare Corporation trades at $204.25 (market cap $17.59B). The key difference: ASML Holding NV is far larger — about 39.2× Tenet Healthcare Corporation's market cap, and ASML Holding NV pays a 0.49% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.

ASMLTHC
Market Cap
$688.66B$17.59B
Sector
TechnologyHealth
52-Week High
$1.99K$244.80
52-Week Low
$689.63$148.38
Enterprise Value
$682.20B$27.84B
Dividend Yield
0.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASML Holding NV

ASML trades at $1,797.32, down 0.38% on the day, with technical indicators showing a bullish trend despite recent volatility. The company reported strong Q1 2026 earnings that beat expectations, with revenue reaching $32.67B in 2025 and net income margins of 29.71%. Analyst consensus remains strongly positive with 56.82% buy ratings and a $2,210 price target, though elevated valuation ratios (P/E 61.03) warrant caution.

ASML maintains a dominant position in advanced semiconductor equipment with robust profitability and growth prospects driven by AI infrastructure demand. Key risks include China export restrictions, competitive pressures, and high valuation multiples. The stock offers exposure to critical chip manufacturing technology but requires monitoring of earnings execution and geopolitical developments.

Tenet Healthcare Corporation

Tenet Healthcare (THC) trades at $204.25, down 1.22% amid broader market weakness. The stock maintains strong fundamentals with a P/E of 10.62 and robust profitability metrics including 37.87% ROE. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show bullish momentum despite overbought RSI readings, with support at $204 and resistance at $209.

The outlook remains positive with 81% analyst buy ratings and a $233.63 consensus price target representing 14% upside. Key risks include healthcare regulatory pressures and execution challenges in outpatient expansion. Earnings growth from the Ambulatory Care segment and defensive positioning during geopolitical tensions provide catalysts for continued appreciation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASML Holding NV

Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.

Read more on ASML

About Tenet Healthcare Corporation

Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.

Read more on THC